Craig Hallum initiated coverage on LifeMD with a new price target
$LFMD
Medical/Nursing Services
Health Care
Craig Hallum initiated coverage of LifeMD with a rating of Buy and set a new price target of $10.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/10/2024 | $12.00 | Buy | Lake Street |
| 12/4/2024 | $7.00 | Neutral | Mizuho |
| 8/23/2024 | $11.00 | Buy | B. Riley Securities |
| 6/5/2024 | $12.00 | Overweight | KeyBanc Capital Markets |
| 11/30/2023 | $10.00 | Buy | Craig Hallum |
| 7/21/2023 | $7.00 | Overweight | Cantor Fitzgerald |
| 7/3/2023 | $9.00 | Buy | H.C. Wainwright |
| 3/10/2022 | $14.00 | Buy | Colliers Securities |
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno
NEW YORK, June 20, 2023 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of William (Will) J. Febbo, Chief Executive Officer and Director of OptimizeRx Corporation (NASDAQ:OPRX) to its Board of Directors. OptimizeRx is a leading provider of digital point-of-care technology solutions that help patients start and stay on therapy. "We are extremely pleased to welcome Will to our Board. He brings to LifeMD a depth of experience in building and managing healthcare companies, and pioneering technology to improve the experience for healthcare providers and patients," said Justin Schreiber, Chairman and Chief Exec
Medifast (NYSE:MED), the health and wellness company known for its habit-based and coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2025. First Quarter 2025 Revenue of $115.7 million, with revenue per active earning coach of $4,556 Independent active earning OPTAVIA coaches of 25,400 Net loss of $0.8 million, which includes an unrealized gain on investment in LifeMD (NASDAQ:LFMD) common stock of $0.4 million (net of tax) Loss per share of $0.07 Cash, Cash Equivalents, and Investment Securities of $164.6 million with no debt "In today's health and wellness landscape, more people than ever are seeking guidance not just for we
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on May 6, 2025 and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Tuesday, May 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-225-9448International Dial-In:203-518-9708Conference ID:LIFEMDLive & Archived Webcast:Link About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, a
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the acquisition of key assets from Optimal Human Health MD ("Optimal"), a nationwide women's health virtual care provider. This strategic acquisition marks LifeMD's official entry into the women's health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness. With women's health historically underserved—particularly in areas such as perimenopause, menopause, and hormonal balance—LifeMD's expansion addresses
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
4 - LifeMD, Inc. (0000948320) (Issuer)
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced a limited-time $299 introductory bundle for new self-pay patients prescribed Wegovy® (semaglutide), which includes both the medication and access to LifeMD's virtual weight management program. As part of its collaboration with Novo Nordisk announced last month, LifeMD is offering Wegovy® at a discounted price of $199 for eligible patients through its recently completed integration with NovoCare® Pharmacy, with an additional $100 covering LifeMD's clinical care, onboarding, and ongoing support. The collaboration with Novo Nordisk strengthens LifeMD's a
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of May: H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq, May 20 in New York City. Management will be holding one-on-one meetings with investors.B. Riley Securities 25th Annual Institutional Investor Conference, May 21-22 at the Ritz-Carlton in Marina Del Rey. Management will be presenting a corporate overview and will be holding one-on-one meetings with investors.Craig-Hallum 22nd Annual Institutional Investor Conference, May 28 at The Depo
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announced plans to offer broad, affordable, and streamlined access to Wegovy® (semaglutide) through NovoCare® Pharmacy. This integration offers a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD's virtual care platform. LifeMD's weight management program is one of the fastest-growing cash-pay offerings in the country, delivering virtual consultations, lab testing, diet and lifestyle support, and prescriptions to anti-obesity medications including GLP-1s when clinically appropriate, within a single,
Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00
Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00
B. Riley Securities resumed coverage of LifeMD with a rating of Buy and set a new price target of $11.00
10-Q - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
8-K - LifeMD, Inc. (0000948320) (Filer)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G/A - LifeMD, Inc. (0000948320) (Subject)
SC 13G - LifeMD, Inc. (0000948320) (Subject)